Cardioprotective Potential of Sodium-Glucose Co-Transporter-2 Inhibitors in Cancer Patients Treated With Anthracyclines: An Observational Study

This study aims to evaluate the safety and potential of SGLT2i for preventing cardiotoxicity in cancer patients, without pre-existing heart failure (HF), receiving anthracyclines therapy.

Source: The American Journal of Cardiology - April 29, 2024 Category: Cardiology Authors: Ayman R. Fath, Mostafa Aglan, Amro Aglan, Robert J. Chilton, Anatole Trakhtenbroit, Odaye A. Al-Shammary, Oduro Oppong-Nkrumah, Daniel J. Lenihan, Susan F. Dent, Prince Otchere Source Type: research